Price
1,397.1
+7.9%52W Range
Market Cap
₹962.88 Cr
Traded: ₹0.64 Cr (0.07%) 0.0x
Free Float: ₹245.15 Cr (0.26% of FF traded)
Volume · 60D trend
4.54 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +11.0% | +11.0% | +17.0% | -- | +1.0% | Stable |
| Profit | -- | -- | -- | -- | +34.0% | -- |
| Return | -- | +27.0% | +57.0% | +20.0% | -- | Stable |
| ROE | +7.0% | +3.0% | -1.0% | -- | -- | Decelerating |
Quarterly Results
Mar 2023
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 94 | 100 | 65 | 65 | 116 | 104 | 72 | 72 | 93 | 68 | 60 | 60 | 70 | 51 | 59 |
| Expenses | 85 | 100 | 63 | 64 | 102 | 102 | 69 | 79 | 88 | 67 | 53 | 55 | 59 | 45 | 56 |
| Operating Profit | 9 | -1 | 2 | 1 | 14 | 2 | 4 | -8 | 4 | 1 | 7 | 4 | 10 | 6 | 3 |
| OPM % | 9.1% | -0.5% | 2.7% | 1.3% | 11.9% | 2.1% | 5.0% | -10.7% | 4.8% | 1.5% | 11.1% | 7.2% | 14.9% | 12.2% | 4.5% |
| Other Income | 1 | 4 | 1 | 4 | 1 | 2 | 3 | 4 | 3 | 3 | 1 | 3 | 2 | 0 | 3 |
| Interest | 2 | 3 | 3 | 3 | 4 | 4 | 3 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 9 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 4 | 2 | 2 | 2 | 1 | 1 |
| Profit Before Tax | -2 | -8 | -8 | -7 | 3 | -8 | -6 | -15 | -5 | -1 | 5 | 5 | 10 | 4 | 4 |
| Tax % | 138.0% | -2.5% | 16.8% | 17.6% | 133.7% | 13.6% | 43.0% | 13.9% | 85.3% | 88.2% | 33.5% | 46.5% | 30.5% | 47.1% | 36.5% |
| Net Profit | -4 | -8 | -10 | -9 | -1 | -9 | -8 | -18 | -9 | -3 | 4 | 2 | 7 | 2 | 2 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 1.5 | -7.0 | -6.4 | -10.5 | 11.9 | -6.9 | -2.4 | -11.5 | 2.0 | -0.5 | 6.5 | 6.0 | 13.0 | 4.3 | 4.9 |
| Sales Growth (YoY) | -19.2% | -4.2% | -9.8% | -9.8% | 25.4% | 53.3% | 20.8% | 19.8% | 32.3% | 33.1% | 1.4% | -27.0% | 168.0% | -- | -- |
| Sales Growth (QoQ) | -- | 52.8% | 0.9% | -44.3% | 11.6% | 43.9% | 0.9% | -22.6% | 36.4% | 13.4% | 0.0% | -14.4% | 37.2% | -13.6% | -- |
| OP Growth (YoY) | -38.1% | -123.3% | -52.2% | 110.8% | 206.9% | 123.0% | -44.9% | -277.3% | -57.0% | -83.9% | 150.4% | -- | -- | -- | -- |
| OP Growth (QoQ) | 1740.4% | -129.9% | 109.6% | -94.0% | 517.9% | -38.7% | 147.5% | -270.6% | 349.0% | -84.9% | 53.0% | -58.7% | 68.0% | 135.6% | -- |
| Profit Growth (YoY) | -88.0% | -1.0% | -163.0% | 4.0% | 543.0% | -1477.0% | -144.0% | -313.0% | -83.0% | -112.0% | 33.0% | -65.0% | 543.0% | -38.4% | 113.0% |
| EPS Growth (YoY) | -- | -1.5% | -163.2% | 8.8% | 509.2% | -1219.2% | -137.2% | -290.1% | -85.0% | -112.1% | 31.6% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | -9.3% | 39.3% | -187.9% | 274.1% | -183.5% | 79.0% | -686.7% | 476.9% | -108.0% | 7.4% | -53.5% | 202.1% | -12.8% | -- |
| OP Margin | -- | -0.5% | 2.7% | 1.3% | 11.9% | 2.1% | 5.0% | -10.7% | 4.8% | 1.5% | 11.1% | 7.2% | 14.9% | 12.2% | 4.5% |
| Net Margin | -- | -8.2% | -14.8% | -13.3% | -0.8% | -9.1% | -10.9% | -24.4% | -9.6% | -3.8% | 6.1% | 4.1% | 10.0% | 4.5% | 4.2% |
| Material Cost % | 49.4% | 58.0% | 49.5% | 47.2% | 59.4% | 51.5% | 49.4% | 58.2% | 59.0% | 65.0% | 61.2% | 62.2% | 57.9% | 59.0% | 67.1% |
| Employee Cost % | 20.1% | 18.5% | 26.1% | 25.5% | 13.2% | 17.4% | 15.2% | 14.8% | 10.7% | 9.8% | 8.9% | 9.8% | 7.1% | 11.0% | 7.6% |
| P/S | 2.98 | 2.91 | 2.47 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.99 | 3.13 | 2.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Intimation for publication of Pre-Newspaper Advertisement of the 33rd Annual General Meeting of the Company.
Intimation regarding permission to trade and Admission of Equity Shares to dealing on the National Stock Exchange of India Limited.
Please find the enclosed newspaper notice to the physical Shareholders informing them about the special window open for re-lodging the transfer deed.
Press release on Update on Expansion and Enhancement of the facility of Varenyam Biolifesciences Pvt Ltd, a Wholly Owned Subsidiary Company of Bharat Parenterals Limited
Intimation of an analyst and investor Meet under Regulation 30 of SEBI (LODR), Regulations, 2015.
Copy of newspaper advertisement for the Unaudited Financial Results for the Quarter ended on June 30, 2026.
Outcome of Board Meeting held on August 05, 2026
Unaudited Financial Results for the quarter ended on June 30, 2026.
Compliance Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended on June 30, 2026
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Desai Shares & Stock Pvt Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Desai Shares and Stock Pvt Ltd
Disclosure Under Regulation 7(2) of SEBI (PIT) Regulations, 2015
Newspaper Advertisement Under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation for the closure of Trading Window in terms of SEBI (Prohibition of Insider Trading) Regulations, 2015.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Desai Shares & Stocks Pvt Ltd
Disclosure under regulation 7(2) of SEBI (PIT) Regulations, 2015.
Annual Secretarial Compliance report for the Year ended March 31, 2026, Pursuant to regulations 24A of SEBI (LODR) Regulations, 2015.
Newspaper publication of Audited Financial Results of the Quarter and Year ended on March 31, 2026.
Transcript of Earning Conference Call of Q4FY26.
Audio Recording of Q4FY26 Earnings Conference Call
Outcome of Board meeting dated May 18, 2026.
Appointment of Cost Auditor and Internal Auditor of the company.
Board of Directors at its meeting held today, May 18, 2026, recommended a Final Dividend of Rs. 1/- Per Equity Share
Audited Financial Results for the Quarter and Year ended on March 31, 2026.
Investor Presentation for the Quarter and Year ended on March 31, 2026.
Intimation of Q4FY26 and FY26 Earnings Conference Call.
Bharat Parenterals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2026 ,inter alia, to consider and approve The standalone and consolidated ....
Newspaper Advertisement Under Regulation 30 of SEBI LODR (Listing Obligations and Disclosure Requirements), Regulations 2015.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Outcome of the U.S. FDA Inspection at Innoxel Lifesciences Private Limited subsidiary Company of Bharat Parenterals Limited
The Exchange has sought clarification from Bharat Parenterals Ltd on April 9, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Clarification w.r.t query raised by BSE for clarification on the Price Movement of our security.
Compliance Certificate under regulation 74(5) of the SEBI (DP) Regulations, 2018 for the quarter ended on March 31, 2026.
Please find the enclosed newspaper notice to physical shareholders informing them about the special window for re-lodge the share transfer deed.
Intimation for the closure of the trading window in terms of SEBI (Prohibition of Insider Trading ) Regulations, 2015.
Please find the enclosed newspaper notice to physical shareholders informing them about the special window to re-lodge the transfer deed.
copy of newspaper advertisement for the unaudited financial results for the quarter and nine months ended December 31, 2025.
Outcome of Board Meeting held on January 30, 2026.
Investor Presentation for the Quarter and Nine Months Ended on December 31, 2025.
Unaudited Financial Results for the Quarter and Nine Months Ended on December 31, 2025.
Bharat Parenterals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Newspaper Advertisement under regulation 30 of SEBI LODR(Listing Obligations and Disclosure Requirements), Regulations, 2015.
Compliance certificate as per regulation 74(5) of SEBI (DP) Regulations, 2018.
Newspaper Advertisement under Regulation 30 of SEBI LODR (Listing Obligations and Disclosures Requirements) Regulations, 2015.
Newspaper Advertisement under Regulation 30 of SEBI LODR (Listing Obligations and Disclosures Requirements) Regulations, 2015.
Newspaper Publication- Last Reminder Notice of special Window for Re-lodgement of Transfer Request of Physical Shares.
Appointment of Mr. Keval Sanjaykumar. Shah as a Vice President- Operations of the company.
Newspaper Advertisement under regulation 30 of SEBI LODR(Listing Obligations and Disclosure Requirements) Regulations, 2015.
Intimation for the Closure of Trading Window in terms of SEBI (Prohibition of Insider Trading) Regulations, 2015.
Newspaper Advertisement under regulation 30 of SEBI LODR (Listing Obligations Disclosure Requirements) regulations, 2015.
Annual Reports
14Concalls
6Jan 2026
31 Jan 2026Nov 2025
30 Nov 2025Jul 2025
31 Jul 2025May 2025
31 May 2025May 2024
31 May 2024Feb 2024
29 Feb 2024